Nematode

Nematode

Cefotaxime Dosage

H. Sumano1, Lilia Gutierrez2, L. Ocampo3
1Department of Physiology and Pharmacology, College of Veterinary Medicine, National Autonomous University of Mexico 04510 Mexico City, Mexico
2Department of Physiology and Pharmacology, School of Veterinary Medicine, National Autonomous University of Mexico Mexico City 04510, Mexico
3Department of Physiology and Pharmacology, College of Veterinary Medicine, National Autonomous University of Mexico 04510 Mexico City, Mexico


Abstract
Considering the already known pharmacological features of cefotaxime, a study with two approaches of pharmacokinetics and clinical efficacy in septicaemic dogs was carried out. Pharmacokinetic variables were defined for doses of 10 mg/kg, and 20 mg/kg, utilising a quantitative bacteriological analysis. Values for half-life (T½ß) at 10 mg/kg were 0.8, 1.48 and 1.52 h for the i.v., s.c. and i.m. routes, respectively. Corresponding values for the 20 mg/kg dose for the same routes were 0.8, 1.49 and 1.53 h, respectively. Relatively fast clearance (ranging from 0.58 to 0.64 L/kg/h) allowed a maximum dose interval of 12 h. The above-stated doses of cefotaxime were administered i.v. to 40 cases of septicaemia, clinically divided into 20 moderately severe cases treated with 10 mg/kg i.v., of cefotaxime bid, and 20 severe ones, treated with 20 mg/kgi.v. of cefotaxime bid. Injections continued until a previously defined criterion of 'clinically recovered' was obtained. Thereafter, a follow-up treatment was established using the same dose and dose-interval but through the s.c. route. Due to the apparent volumes of distribution obtained (ranging from 0.48 to 0.51 L/kg), considering the overall clinical efficacy obtained (90% for the 10 mg/kg dose and 75% for the 20 mg/kg dose), and due to the rapid improvement observed after a few doses of the drug (1.8 to 2.5 doses to 'clinical improvement'), it is safe to postulate such doses of cefotaxime as excellent choices for the treatment of septicaemia in dogs.

Keywords
pharmacokinetics, pharmacokinetics, pharmacokinetics, dogs, Cefotaxime, septicaemia, efficacy
References
Bennet, J. B., Brodie, J. L., Benner, E. J. and Kirby, W. M. (1966): Simplified accurate method for antibiotic assay of clinical specimens. Am. Soc. Microbiol. 14, 170-177.

Billiet, J., Kuypers, S., Van Lierde, S. and Verhaegen, J. (1989): Plesiomonas shigelloides meningitis and septicaemia in a neonate: report of a case and review of the literature. J. Infect. 19, 267-271.

[CrossRef] [PubMed]
Berezhinskaia, V. V., Dolgova, G. V., Egorenko, G. G., Svinogeeva, T. P. and Zebrev, A. I. (1990): General toxic and organotropic properties of cefotaxime in acute and chronic experiments (in Russian). Antibiot. Khimioter. 35, 25-27. 94 SUMANO et al. Acta Veterinaria Hungarica 52, 2004.

[PubMed]
Bocazzi, A., Tonelli, P., Bellosta, C. and Careddu, P. (1998): Clinical and pharmacological evaluation of modified cefotaxime bid regimen vs.traditional tid in pediatric lower respiratory tract infections. Diagn. Microbiol. Infect. Dis. 32, 265-272.

[CrossRef] [PubMed]
Carli, S., Anfossi, P., Villa, R., Castellani, G., Mengozzi, G. and Montesissa, C. (1999): Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular. J. Vet. Pharmacol. Therap. 22, 308-313.

[CrossRef] [PubMed]
Chamberland, S., Blais, J., Hoang, M., Dinh, C., Cotter, D., Bond, E., Gannon, C., Park, C., Halovin, F. and Dudley. M. N. (2001): In vitro activities of RWJ-54428 (MC-02,479) against multiresistant Gram-positive bacteria. Antimicrob. Agents Chemother. 45, 1422-1430.

[CrossRef] [PubMed]
De Sarro, A., Ammendola, D., Zappala, M., Grasso, S. and De Sarro, G. B. (1995): Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob. Agents Chemother. 39, 232-237.

[PubMed]
Diaz, A. J., Sumano, L. H., Ocampo, C. L. and Mateos, T. G. (1995): Evaluación de la nefrotoxicidad en la administración conjunta de cefalexina sódica y sulfato de gentamicina en perros. Vet. Méx. 26, 247-249.

Fernandez, G. M., Lumbreras, J. M., Sanchez, J. A. and Ordoñez, D. (1991): The interaction of cefotaxime with the serum albumin of several mammalian species. Comp. Biochem. Physiol. 100, 413-415.

[CrossRef]
Gardner, S. Y. and Papich, M. G. (2001): Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs. J. Vet. Pharmacol. Therap. 24, 187-192.

[CrossRef] [PubMed]
Guerrini, V. H., English, P. B., Filippich, L. J., Schneider, J., Pharm, B. and Bourne, D. W. A. (1986): Pharmacokinetic evaluation of a slow-release cefotaxime suspension in the dog and in sheep. Am. J. Vet. Res. 47, 2057-2061.

[PubMed]
Harpster, N. K. (1981): The effectiveness of the cephalosporins in the treatment of bacterial pneumonias in the dog. J. Am. Anim. Hosp. Assoc. 17, 766-772.

Hunfeld, K. P., Kraiczy, P., Wichelhaus, T. A., Schafer, V. and Brade, V. (2000): Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int. J. Antimicrob. Agents 15, 11-17.

[CrossRef] [PubMed]
Lavy, E., Ziv, G., Aroch, I. and Glickman, A. (1995): Clinical pharmacologic aspects of cefixime in dogs. Am. J. Vet. Res. 56, 633-638.

[PubMed]
MacDonald, C. M., Fromson, J. M., McDonald, A., Dell, D., Chamberlain, J. and Coombes, J. D. (1984): Disposition of cefotaxime in rat, dog and man. Arzneimittel Forsch. 14, 1719-1723.

Morris, D. D., Rutkowski, J. and Lloyd, K. C. K. (1987): Therapy in two cases of neonatal foal septicaemia and meningitis with cefotaxime sodium. Equine Vet. J. 19, 151-154.

[PubMed]
Nakano, S., Yada, H., Irimura, K., Kurokawa, K., Hirota, T. and Morita, K. (1988): Five-week subacute intravenous toxicity study of cefodizime sodium in dogs. J. Toxicol. Sci. 1, 43-90.

Nau, R., Prange, H. W., Muth, P., Mahr, G., Menck, S., Kolenda, H. and Soigel, F. (1993): Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob. Agents Chemother. 37, 1518-1524.

[PubMed]
Navasa, M., Follo, A., Llovet, J. M., Clemente, G. and Vargas, V. (1996): Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 111, 1011-1017.

[CrossRef] [PubMed]
Nostrandt, A. C. (1990): Bacteremia and septicemia in small animal patients. Prob. Vet. Med. 2, 348-361.

Petersen, S. and Rosin, W. E. (1993): In vitro antibacterial activity of cefoxitine and cefotetan and pharmacokinetics in dogs. Am. J. Vet. Res. 54, 1496-1499.

[PubMed]
Quinn, P. J., Carter, M. E., Markey, B. and Carter, G. R. (1994): Clinical Veterinary Microbiology. Wolfe Publishing Co., London, UK. pp. 118-343.

Riviere, J. E. (1999): Comparative Pharmacokinetics. Principles, Techniques and Applications. Iowa University Press, Ames, Iowa.

Rubinstein, E. and Lang, R. (1992): Once-a-day beta-lactam antibiotic administration. J. Clin. Pharmacol. 32, 711-715.

[PubMed]
Schermerhorn, T., Barr, S. C., Stoffregen, D. A., Koren-Roth, Y. and Erb, H. N. (1994): Wholeblood platelet aggregation, buccal mucosa bleeding time, and serum cephalothin concentration in dogs receiving a presurgical antibiotic protocol. Am. J. Vet. Res. 55, 1602-1608.

[PubMed]
Sharma, S. K., Srivastava, A. K. and Bal, M. S. (1995): Disposition kinetics and dosage regimen of cefotaxime in cross-bred male calves. Vet. Res. 26, 168-173.

[PubMed]
Sumano, L. H. and Borbolla, S. G. (1986): Actualidades de la terapia antimicrobiana del choque séptico. Mi Mascota. 4, 23-31.

Sumano, L. H. and Brumbaugh, G. W. (1995): Farmacología clínica de los aminoglicósidos y los aminociclitoles en medicina veterinaria. Vet. Méx. 26, 1-15.

Sumano, L. H. and Ocampo, C. L. (1992): Farmacología Veterinaria. 2nd edition, 1992. McGraw-Hill, México, DF. pp. 125-138.

Sumano, L. H., Ocampo, C. L. and Pulido, E. (2000): Manual de farmacología clínica para pequeñas especies. 2nd edition, 2000. Laboratorios Virbac, México, DF. pp. 35-41.

Teshager, T., Dominguez, L., Moreno, M. A., Saenz, Y., Torres, C. and Cardenosa, S. (2000): Isolation of an SHV-12 beta-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections. Antimicrob. Agents Chemother. 44, 3483-3484.

[CrossRef] [PubMed]
Turnidge, J. D. (1995): Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Diagn. Microbiol. Infect. Dis. 22, 57-69.

[CrossRef] [PubMed]
Trudel, J. L., Wittnich, C. and Brown, R. A. (1994): Antibiotics bioavailability in acute experimental pancreatitis. J. Am. College. Surg. 178, 475-479.

Tsai, T. H., Chen, Y. F., Chen, K. C., Shum, A. Y. and Chen, C. F. (2000): Concurrent quantification and pharmacokinetic analysis of cefotaxime in rat blood and brain by microdialysis and microbore liquid chromatography. J. Chromatogr. 738, 75-81.

[CrossRef]
Viladrich, P. F., Cabellos, C., Pallares, R., Tubau, F., Martinez-Lacasa, J., Linares, J. and Gudiel, F. (1996): High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob. Agents Chemother. 40, 218-220.

[PubMed]
Wang, R., Fang, Y. and Du, L. H. (1998): Influencing factors of postantibiotic effect of 4 cephalosporins. Chin. J. Clin. Pharmacy 7, 77-80.

Withrow, S. J. (1979): Dental extraction as a probable cause of septicemia in a dog. J. Am. Anim. Hosp. Assoc. 115, 345-346.

Ziv, G., Cohen, R. O., Winkler, M. and Saran, A. (1996): Antimicrobial susceptibility of Escherichia coli and Streptococcus sp. recovered from the uterus of dairy cows with post parturient metritis. Israel J. Vet. Med. 51, 63-66.
more options Find
Query Builder Close | Clear Title (ti) Summary (su) Author (au) ISSN (issn) ISBN (isbn) DOI (doi) And Or Not ( ) * (wildcard) Within all content
Within this journal
Within this issue

canine parvo viral treatment

Canine Parvovirus Enteritis
by Dr. Randy Wetzel

Canine parvovirus (CPV) enteritis is a common cause of acute, severe gastroenteritis in young dogs. Dogs at greatest risk are less than 6 months of age and either unvaccinated or incompletely vaccinated for canine parvovirus. Dogs vaccinated with over-the-counter vaccines also appear to have a higher incidence of parvovirus likely due to ineffective vaccine or improper use. Early clinical signs of parvovirus enteritis include anorexia, lethargy, diarrhea and vomiting.

Parvovirus enteritis has a survival rate of 85-90% with aggressive treatment and recovery generally occurs in 3-7 days. For patients who do not receive aggressive and appropriate treatment, the mortality rates increase substantially. Death is generally due to sepsis and/or dehydration. Correcting dehydration and electrolyte imbalances and reducing further fluid loss is critical to successfully managing these patients. For most patients this requires hospitalization on IV fluids, IV antibiotics, antiemetics, and GI protectants as the mainstay of treatment. Once a patient is hydrated, we find synthetic colloids such as Hetastarch (20ml/kg/day CRI) beneficial in replacing intravascular volume, maintaining hydration and managing shock. Synthetic colloids are excellent in their ability to increase COP which is often a concern in patients with hypoalbuminemia and increased capillary permeability as is often the case with so many CPV enteritis patients. Use of synthetic colloids generally permits you to decrease crystalloid fluid rates by 40-60%. Natural colloids such as fresh frozen plasma (FFP) or fresh whole blood (FWB) may be beneficial for anemic patients or those needing further immune support. In addition to providing oncotic components, both whole blood and plasma contain antibodies and serum protease inhibitors which may be beneficial in neutralizing circulating virus and controlling the systemic inflammatory response associated with the disease.

Parvovirus patients are often suffering from bone marrow suppression and their immune systems are overwhelmed by the viral infection making them at high risk of sepsis. We use broad-spectrum antibiotics such as Ampicillin, 22mg/kg IV TID, and amikacin 10mg/kg, IV TID, once the patient is hydrated. For patients with leukopenia, enrofloxacin at 5mg/kg IV BID diluted 1:1, is considered safe to use short term (3-5 days). Butorphanol 0.3mg/kg IV is recommended for abdominal pain, and a lower dose (0.15mg/kg) has been suggested in the medical management of patients suspected of having intussusception.

Tamilflu (oseltamivir phosphate) (1mg/kg PO BID for 5 days) used to treat influenza in people has anecdotally shown to be beneficial in treating CPV enteritis and thought to reduce viral replication.
Monitoring a complete blood count (CBC) is beneficial in evaluating a patient's condition. Patients with severe leukopenia raise concern about bone marrow suppression and risk of sepsis. I often find a poor correlation between the physical exam and attitude of the patient compared to the leukogram count. However, I do find positive correlation in patients with a low leukogram count and increased morbidity. These patients may benefit from more aggressive treatment immediately.

Treating patients with CPV enteritis is labor intensive and costly. A proper isolation ward and isolation protocol is important for reducing contamination to other patients. The profuse amount of vomiting and diarrhea makes proper isolation protocol challenging.

Parvovirus is shed in the feces by infected animals and this virus can remain stable in the environment for 7 months or longer. These viral particles can be transferred on the shoes, hands and clothes of people who then may expose an unprotected dog. It is very important to understand the ease of transmission and the fact that direct contact between the unprotected dog and the infected dog is not necessary for a pet to become exposed. Reducing risk of exposure is necessary, but it is vital to have pets inoculated with an effective vaccine at the appropriate time and properly administered. As an emergency clinician, I commonly see cases of parvovirus enteritis in patients who were vaccinated with vaccines attained through feed stores. The frequency at which this occurs raises a concern that the vaccines being used are ineffective or perhaps inappropriately administered. I commonly see mistakes in the timing of the vaccination when they are administered at home. It is important to understand the cycle of a puppy’s immune system with regard to maternal antibodies and duration of response to vaccination. Therefore initiating vaccination at 6 weeks of age by a veterinarian is strongly recommended.

References:
Rebecca Kirby, DVM, DACVIM, DACVECC
David Miller, BVSc, MMedVet
Douglass K. Macintire, DVM, MS, DACVIM, DACVECC
Alice M. Wolf, DVM, DACVIM, DABVP

Amikacine Dose rate Canines

Description
Amikacin sulfate is a semi-synthetic aminoglycoside antibiotic derived from kanamycin. It is C22H43N5O13•2H2SO4,D-streptamine, 0-3-amino-3-deoxy- α- D-glucopyranosyl-(1→6)-0-[6-amino-6-deoxy- α - D-glucopyranosyl-(1→4)]-N1-(4-amino-2- hydroxy-1- oxobutyl)-2-deoxy-,(S)-, sulfate (1:2)(salt).


The dosage form supplied is a sterile, colorless to straw colored solution containing, in addition to amikacin sulfate, 2.5% sodium citrate, pH adjusted with sulfuric acid, 0.66% sodium bisulfite added, and 0.1 mg benzethonium chloride per mL as a preservative.

Each Ml Of Solution Contains
Amikacin (as the sulfate)
50 mg

Sodium citrate, USP (as buffer)
25.1 mg

Sodium bisulfite
6.6 mg

Benzethonium chloride, USP (as preservative)
0.1 mg

Water for injection, USP
q.s.


pH adjusted with sulfuric acid.

Action
Amikacin, like other aminoglycoside antibiotics, is a bactericidal agent that exerts its action at the level of the bacterial ribosome. Amikacin has been shown to be effective against many aminoglycoside-resistant strains due to its ability to resist degradation by aminoglycoside inactivating enzymes known to affect gentamicin, tobramycin and kanamycin(1).

Microbiology
Amikacin has been shown to be effective in the treatment of skin and soft tissue infections caused by Pseudomonas sp and Escherichia coli and in urinary tract infections caused by Escherichia coli and Proteus sp. The susceptibility of veterinary isolates to amikacin is summarized in the following table:

Organism (no. Of Isolates) Minimum Inhibitory Concentration (mcg/ml)
Range Mic90*
Escherichia coli (50)
1-32
4

Proteus mirabilis (50)
1-128
6

Enterobacter sp. (50)
0.5-128
4

Staphylococcus aureus (50)
1-128
2

Klebsiella pneumoniae (50)
0.5-16
2

Pseudomonas aeruginosa (50)
1-64
8


*Concentration at which 90% of the isolates are susceptible.

In addition, the following microorganisms have been shown to be susceptible to amikacin in vitro(2), although the clinical significance of this action has not been demonstrated in animals:

Serratia marcescens, Salmonella sp, Shigella sp, Providencia sp, Citrobacter freundii, Listeria monocytogenes

The aminoglycoside antibiotics in general have limited activity against gram-positive pathogens, although Staphylococcus aureus and Listeria monocytogenes are susceptible to amikacin as noted above.

Pharmacokinetics
Amikacin is well absorbed following intravenous, subcutaneous, or intramuscular injection but is not appreciably absorbed orally. The serum half-life (T1/2) averages from 1 to 2 hours in dogs depending on the route of administration(3). Amikacin is excreted unchanged in urine, concentrations in excess of 1,000 mcg/mL typically being achieved within three hours in dogs. Serum concentration-time profiles in dogs following subcutaneous administration are illustrated graphically in Figure 1.


Figure 1
Amikacin Concentration-Time Curves in Dogs (n=6) Following Subcutaneous Injection
Toxicology
The intravenous and intramuscular LD50 in dogs is greater than 250 mg/kg. Like other aminoglycosides, amikacin has nephrotoxic, neurotoxic, and ototoxic potential. In dogs, minimal to mild renal changes were detectable histopathologically after amikacin dosage of 45 mg/kg/day for two weeks, and dogs receiving a dosage of 30 mg/kg/day for 90 days had minimal renal alterations which were believed to be entirely reversible. Urinary casts were not observed in dogs receiving a 30 mg/kg dose for 90 days. In efficacy studies involving 80 infected dogs treated with amikacin at the recommended dosage rate of 10 mg/kg b.i.d. for 8-21 consecutive days, no evidence of nephrotoxicity or any other toxicity was encountered. Regarding ototoxicity, studies in cats reveal that amikacin has less potential for ototoxicity than gentamicin(4).

Amikacin K-9 Injection Indications
Amikacin K-9 Injection (Amikacin Sulfate Injection) is indicated for the treatment of the following conditions in dogs: Genitourinary tract infections (cystitis) caused by susceptible strains of Escherichia coli and Proteus sp. Skin and soft tissue infections caused by susceptible strains of Pseudomonas sp and Escherichia coli.

While nearly all strains of Escherichia coli, Pseudomonas sp, and Proteus sp, including those that are resistant to gentamicin, kanamycin or other aminoglycosides, are susceptible to amikacin at levels achieved following treatment, it is recommended that the invading organism be cultured and its susceptibility demonstrated as a guide to therapy. Amikacin susceptibility discs, 30 mcg, should be used for determining in vitro susceptibility.

Contraindications
Systemic aminoglycoside therapy is contraindicated in dogs with seriously impaired renal function.

Precautions
The following conditions have been found to contribute to the toxicity of aminoglycosides in dogs:

-Prior renal damage (most commonly found in dogs of advanced age) and dogs infected with heartworm microfilaria.(5)

-Hypovolemic dehydration (dehydrated patients should be rehydrated prior to initiating therapy).

In dogs where decreased renal function is suspected prior to treatment, BUN or serum creatinine levels may not indicate the degree of kidney impairment. A creatinine clearance determination may be more useful.

Monitoring of renal function during treatment is recommended. Although there is not a completely reliable monitoring program for aminoglycoside toxicity, urinalysis may indicate early nephrotoxicity. Unfavorable changes in the urinalysis which may indicate toxicity include:

-Decreased specific gravity in the absence of fluid therapy.

-Appearance in the urine of casts, albumin, glucose or blood.

Continued use of aminoglycosides where any functional renal impairment has occurred may lead to enhanced renal damage as well as increased likelihood of ototoxicity and/or neuromuscular blockade.(6)

Concurrent or sequential use of topically or systemically administered nephrotoxic, ototoxic, or neuromuscular blocking drugs, particularly other aminoglycosides such as streptomycin, gentamicin, kanamycin and neomycin should be avoided because of the potential for additive effects.

Concurrent administration of furosemide with aminoglycosides may enhance nephrotoxicity.(7)

Not for use in breeding dogs as reproductive studies have not been conducted.

Neurotoxic and nephrotoxic antibiotics may be absorbed in significant quantities from body surfaces after local irrigation or application. The potential toxic effect of antibiotics administered in this fashion should be considered.(8)

If hypersensitivity develops, treatment with Amikacin K-9 Injection (Amikacin Sulfate Injection) should be discontinued and appropriate therapy instituted.

Warning
Amikacin should be used with extreme caution in dogs, in which hearing acuity is required for functioning, such as seeing eye, hearing ear or military patrol, as the auditory and vestibular impairment tends not to be reversible.(6)

Aminoglycosides, including amikacin, are not indicated in uncomplicated episodes of cystitis unless causative agents are susceptible to them and are not susceptible to antibiotics having less potential for toxicity.

Early signs of ototoxicity can include ataxia, nausea and vomiting. Auditory and vestibular impairment may be reversible in the very early stages, but if treatment is continued, the conditions will become irreversible.(6)

Adverse Reactions
In clinical studies in dogs, transient pain on injection has been reported as well as rare cases of vomiting or diarrhea following amikacin therapy. In 90 day intramuscular toxicology studies, evidence of muscle damage was detected histologically as well as by elevated creatinine phosphokinase.

Amikacin K-9 Injection Dosage And Administration
Amikacin K-9 Injection (Amikacin Sulfate Injection) should be administered subcutaneously or intramuscularly at a dosage of 10 mg/kg (5 mg/lb) twice daily. Dogs with skin and soft tissue infections should be treated for a minimum of 7 days and those with genitourinary infections should be treated for 7 to 21 days or until culture negative and asymptomatic. If no response is observed after three days of treatment, therapy should be discontinued and the case re-evaluated. Maximum duration of therapy should not exceed 30 days.

Amikacin K-9 Injection Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Supply
50 mL vial, 50 mg/mL, Amikacin K-9 Injection (Amikacin Sulfate Injection).

Store vials between 15° and 30°C, (59° and 86°F). At times the solution may become pale yellow in color. This does not indicate a decrease in potency.

References
1.Davies, J., Courvalin, P.: Mechanisms of Resistance to Aminoglycosides. Am. J. Med. 62: 868-872, 1977.

2.Price, K.E., et al: Microbiological Evaluation of BB-K8, a New Semisynthetic Aminoglycoside. J. Antibiot. 25: 709-731, 1972.

3.Baggot, J.D., Ling, G.V., and Chaffield, R.C.: The Pharmacokinetics of Amikacin in Dogs. Am. J. Vet. Res., 46:1793-1796, 1985.

4.Christensen, E.F., Reiffenstein, J.C., and Madissoo, H.: Comparative Ototoxicity of Amikacin and Gentamicin in Cats. Antimicrob. Agents Chemother. 12: 178-184, 1977.

5.Casey, H.W., D.K. Obeck and G.A. Splitter, "Immunopathology Studies on Canine Heartworm", Canine Heartworm Disease, the Current Knowledge, University of Florida Press, 31-32, 1973.

6.Kirk, R.W., ed., Current Veterinary Therapy VIII Small Animal Practice, W.B. Saunders Company, Philadelphia, PA, 119, 731, 1040, 1983.

7.Raisbeck, M.F., W.R. Hewitt and W.B. McIntyre, "Fatal Nephrotoxicosis Associated with Furosemide and Gentamicin Therapy in a Dog", Journal of American Veterinary Medical Association, 183: 892-893, 1983.

8.Riviere, J.E., and L.E. Davis, 1964, Renal Handling of Drugs in Renal Failure, Harwal Publishers, 666-667, 1984.

600072

Iss. 11-01